Lysosome plays important roles in cellular homeostasis, and its dysregulation contributes to
tumor growth and survival. However, the understanding of regulation and the underlying mechanism of lysosome in
cancer survival is incomplete. Here, we reveal a role for a
histone acetylation-regulated
long noncoding RNA termed lysosome cell death regulator (LCDR) in
lung cancer cell survival, in which its knockdown promotes apoptosis. Mechanistically, LCDR binds to heterogenous nuclear
ribonucleoprotein K (
hnRNP K) to regulate the stability of the lysosomal-associated
protein transmembrane 5 (LAPTM5) transcript that maintains the integrity of the lysosomal membrane. Knockdown of LCDR,
hnRNP K, or LAPTM5 promotes lysosomal membrane permeabilization and lysosomal cell death, thus consequently resulting in apoptosis. LAPTM5 overexpression or
cathepsin B inhibitor partially restores the effects of this axis on lysosomal cell death in vitro and in vivo. Similarly, targeting LCDR significantly decreased
tumor growth of patient-derived xenografts of
lung adenocarcinoma (LUAD) and had significant cell death using nanoparticles (NPs)-mediated systematic
short interfering RNA delivery. Moreover, LCDR/
hnRNP K/LAPTM5 are up-regulated in LUAD tissues, and coexpression of this axis shows the increased diagnostic value for LUAD. Collectively, we identified a
long noncoding RNA that regulates lysosome function at the posttranscriptional level. These findings shed light on LCDR/
hnRNP K/LAPTM5 as potential therapeutic targets, and targeting lysosome is a promising strategy in
cancer treatment.